Twitxy Saved

Jacob Trefethen

Verified account This account is verified. Learn more

@JacobTref

OpenAI Foundation

science!
San Francisco, CA jacobtrefethen.com Joined June 2015
997 Following 8.6K Followers 2.1K Posts

Latest posts 5

Pinned post

Jacob Trefethen Verified account @JacobTref
Alzheimer’s is one of medicine's hardest unsolved problems, and one of the most devastating.

At the OpenAI Foundation, we believe AI is well suited to its complexity. We're directing over $100M to scientists mapping the disease, designing drugs, & more.

I wrote about it here:
openaifoundation.org/news/ai-for-al…
openaifoundation.org AI for Alzheimer’s The OpenAI Foundation is working to finalize more than $100 million in initial grants across six research institutions to support AI for Alzheimer’s research
191 replies 275 reposts 2.3K likes 380K views View on X
Jacob Trefethen Verified account @JacobTref
New episode:
Saloni Verified account @salonium 3d
New episode of HARD DRUGS!

Will AI progress be crushed by Eroom’s law?

Even as technology has advanced, drug development has gotten more and more expensive over time.

In the 1950s, one billion dollars of R&D spending got us roughly fifty new drugs. Today, it gets us about one.

This trend is called Eroom’s law, or Moore’s law spelled backwards. It seems pretty bleak: the R&D cost per new drug has roughly doubled every nine years, in inflation-adjusted dollars, meaning drug development has become exponentially more expensive.

What could explain this? Here are some possibilities:

• Our standards of evidence and requirements for safety testing have risen, through regulation, public expectations, and risk aversion.

• We’ve picked the low-hanging fruit already. Perhaps we’ve already made the easiest discoveries, and diseases that are harder to understand or treat are left.

• Or perhaps it’s the ‘better than the Beatles’ problem: New drugs not only have to be effective, but have to compete with existing treatments, which are already effective. Plus, some of them have gone off-patent and become cheap generics, making the price contrast starker.

Relatedly, as diseases become rarer or milder, it takes more effort to demonstrate that new drugs are effective, with larger or longer clinical trials.

But there are also reasons to question these explanations. We still lack effective treatments for many diseases. And our tools for studying biology have improved enormously. Why hasn’t that been enough?

Will our best efforts be crushed by Eroom’s law, too? Or can AI reverse the trend?

In our latest episode of HARD DRUGS, @JacobTref and I chat about all this and more. Listen wherever you get your podcasts!

Chapters:
00:00 Introduction
02:53 Eroom’s law trivia
12:33 How much does it really cost to develop a drug?
22:35 The better than the Beatles problem
33:06 Clinical trials are larger and more rigorous today
42:01 Have we picked the low-hanging fruit?
01:01:22 Is Eroom’s law slowing down because of rare disease drugs?
01:06:18 Can AI reverse Eroom’s law?
01:15:09 Conclusion
View quoted post on X
2 replies 4 reposts 48 likes 3.2K views View on X
Jacob Trefethen Verified account @JacobTref
Makes you think
Jacob Trefethen Verified account @JacobTref Oct 2
I believe that 1) siRNA will change medicine, with new treatments for tens of diseases, 2) tens of millions of people will take an siRNA drug in the 2030s, with some chance of >100M people, and 3) I will have taken at least one siRNA drug within a decade.

I have never worked on siRNA, and I also don't think of myself as a hypester. So, why the confidence? There's the technical answer, then the structural answer.

The technical answer is that siRNA has several attractive properties as a drug modality, and enough of the chemistry problems have been solved that I'm confident more drug approvals are on the way (though there are many important unsolved problems left, e.g. in delivering siRNA to organs other than the liver). The four most attractive properties are that with siRNA you can reduce production of previously undruggable proteins by going after the RNA that codes for them; they’re “programmable” to a gene/protein you’re going after; siRNA can last long, with slow release inside cells; and siRNA drugs have the potential to be relatively cheaply made and self-administered.

The structural answer, I believe, is biotechnology’s combination of long timelines with particularly un-juicy, hard-to-remember concepts. If something takes 20 years, you can often spot it 10 years in -- but when it’s an acronym and involves chemical conjugation steps, it’s hard to remember to care. Many important ideas in biology are messy and technical and, unless you've caught the bug (intellectual or literal), boring. That means there are many important secrets lying in plain sight, as per @nayafia's last book.

While disagreements and unknowns remain, it is not particularly controversial among scientists that siRNA holds a lot of promise (alongside some realised promise already!) -- and, yet, most people who will benefit from siRNA drugs in the 2030s have never heard of it.

(PS: given my job involves stewarding charitable dollars related to science, I don’t invest in individual pharma/biotech stocks personally; this post isn’t about the financial prospects of particular companies.)
View quoted post on X
3 replies 7 reposts 91 likes 12K views View on X
Jacob Trefethen Verified account @JacobTref
I believe that 1) siRNA will change medicine, with new treatments for tens of diseases, 2) tens of millions of people will take an siRNA drug in the 2030s, with some chance of >100M people, and 3) I will have taken at least one siRNA drug within a decade.

I have never worked on siRNA, and I also don't think of myself as a hypester. So, why the confidence? There's the technical answer, then the structural answer.

The technical answer is that siRNA has several attractive properties as a drug modality, and enough of the chemistry problems have been solved that I'm confident more drug approvals are on the way (though there are many important unsolved problems left, e.g. in delivering siRNA to organs other than the liver). The four most attractive properties are that with siRNA you can reduce production of previously undruggable proteins by going after the RNA that codes for them; they’re “programmable” to a gene/protein you’re going after; siRNA can last long, with slow release inside cells; and siRNA drugs have the potential to be relatively cheaply made and self-administered.

The structural answer, I believe, is biotechnology’s combination of long timelines with particularly un-juicy, hard-to-remember concepts. If something takes 20 years, you can often spot it 10 years in -- but when it’s an acronym and involves chemical conjugation steps, it’s hard to remember to care. Many important ideas in biology are messy and technical and, unless you've caught the bug (intellectual or literal), boring. That means there are many important secrets lying in plain sight, as per @nayafia's last book.

While disagreements and unknowns remain, it is not particularly controversial among scientists that siRNA holds a lot of promise (alongside some realised promise already!) -- and, yet, most people who will benefit from siRNA drugs in the 2030s have never heard of it.

(PS: given my job involves stewarding charitable dollars related to science, I don’t invest in individual pharma/biotech stocks personally; this post isn’t about the financial prospects of particular companies.)
Saloni Verified account @salonium Oct 2
Can we switch off diseases?

siRNA drugs are, in my view and @JacobTref’s too, one of the most exciting developments in medicine. So we decided to do an episode!

It’s a technology that can ‘silence’ harmful genes in the body. And there are lots of cases where you might want to silence genes:

- Infectious diseases, where you can silence pathogen proteins or human proteins that pathogens depend on
- Rare genetic diseases, where you can silence the production of mutated proteins
- Cardiovascular diseases, by silencing proteins that raise cholesterol
- Cancers, by silencing proteins that help tumour cells grow, survive, metabolize, metastasize, or resist treatment
- and more!

What’s even better is that siRNA drugs are:

• Potentially tunable, meaning you could reduce the production of a protein, rather than silencing it entirely
• Programmable, meaning you can quickly switch out which gene it targets by changing its sequence
• Long-lasting: some drugs last for months, even half a year, with a single injection
• Off-the-shelf: they typically don’t involve complicated surgeries or procedures, because of the way they’re delivered in the body

Today, siRNA drugs are largely used to treat liver diseases, partly because that’s the easiest starting point.

And they are extremely effective at it. One example is as a cholesterol drug: siRNAs can reduce PCSK9 levels by around 70%, reducing cholesterol levels by 50-60%, beyond the effect of statins.

But we think it’s just a matter of time before they can be used to target other organs too.

Will siRNA treat diseases of other organs? And what’s the catch?

Listen to our latest episode of HARD DRUGS to find out!

Chapters:
00:00 Introduction
09:58 siRNA trivia
28:14 The 20 year journey to make siRNA drugs
36:07 Which diseases could siRNA treat?
50:45 Programmable, long-lasting, scaleable drugs
54:32 The limits of siRNA
1:08:23 Conclusion
View quoted post on X